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Objectives: A pharmacokinetic comparison of three dosing regimens of saquinavir/ritonavir was
carried out: 1600/100 mg once-daily with 1000/100 mg twice-daily, and 1600/100 mg once-daily with
2000/100 mg once-daily.
Methods: Twenty patients on saquinavir hard gel caps/ritonavir 1600/100 mg once-daily in combination
with two nucleoside reverse transcriptase inhibitors for at least 4 weeks were enrolled and randomized
to either saquinavir hard gel caps/ritonavir 1000/100 mg twice-daily or 2000/100 mg once-daily. Two
pharmacokinetic curves were plotted, at baseline (day 0) and 7 days after the switch. Plasma concen-
trations were measured at 0, 2, 4, 6, 8, 10, 12 (and 24 for once-daily dosing) hours after drug intake by
validated high-performance liquid chromatographic assay (HPLC). The area under the plasma concen-
tration–time curve (AUC0–24 or AUC0–12), maximum and minimum concentration (Cmax and Cmin) and
elimination half-life were calculated using a non-compartmental model.
Results: Compared with saquinavir/ritonavir 1600/100 mg once-daily dosing, the saquinavir AUC and
Cmin improved significantly when dosed as 1000/100 mg twice-daily (53% and 299%, respectively), and
as 2000/100 mg once-daily (71% and 65%, respectively). Low Cmin in three subjects at baseline was cor-
rected after switch to the other dosages. Saquinavir/ritonavir 2000/100 mg once-daily was also asso-
ciated with a significant increase in saquinavir Cmax (52%) compared with saquinavir/ritonavir
1600/100 mg once-daily.
Conclusions: Saquinavir/ritonavir when dosed as 2000/100 mg once-daily or 1000/100 mg twice-daily
achieves higher saquinavir plasma levels compared with saquinavir/ritonavir 1600/100 mg once-daily.
Taking the convenience of once-daily dosing into consideration, dosage of 2000/100 mg once-daily may
be preferred.
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Introduction
Saquinavir is an HIV protease inhibitor. It is used as part of a
therapeutic regimen for HIV-1 or HIV-2 infection. Saquinavir is
frequently combined with low dose ritonavir to improve the
pharmacokinetics of saquinavir. Ritonavir and saquinavir are
metabolized through the same pathways, predominantly by
cytochrome P450 isoenzyme 3A4. Furthermore, inhibition of
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P-glycoprotein, by ritonavir, has been suggested to play a role in
the boosting effect. Improvement of saquinavir pharmacokinetic
parameters enables the use of lower and less frequent saquinavir
dosing.1
Two formulations of saquinavir are available: the saquinavir
hard gel capsule and the saquinavir soft gel capsule. Pharmaco-
kinetic studies have shown that the formulations are bioequiva-
lent when boosted by ritonavir.2,3 Furthermore, in the HIV-NAT
001 study series, virological response was maintained and
immunological recovery continued out to 48 weeks when saqui-
navir soft gel caps/ritonavir was replaced with saquinavir hard
gel caps/ritonavir. Reasons to use saquinavir hard gels caps
instead of saquinavir soft gel caps, include better tolerability,
smaller capsule size, the absence of need for refrigerated storage
and lower cost in most countries.3,4
The recommended dose for saquinavir with low dose of rito-
navir is 1000/100 mg twice-daily. However, a 1600/100 mg dose
has been tested as a once-daily dosing regimen. When dosed as
1600/100 mg, the total daily dose is lower than that received
with the recommended 1000/100 mg twice-daily dose, possibly
leading to suboptimal exposure to saquinavir and virological
failure. Furthermore, for all other protease inhibitors, the total
daily dose is similar for once-daily and twice-daily regimens.
Therefore, a once-daily dosing regimen of 2000/100 mg may
result in better exposure to saquinavir than 1600/100 mg.
The objective of this study was to investigate the pharmaco-
kinetics of 1600/100 mg once-daily, 2000/100 mg once-daily and
1000/100 mg twice-daily in HIV-1-infected patients.
Materials and methods
Patient selection, screening and study design
This was a single-centre, open-label, pharmacokinetic study in
asymptomatic HIV-infected individuals conducted as a substudy of
the STACCATO trial.5 Twenty patients were recruited from The
Thai Red Cross Society’s Anonymous Clinic. Patients were taking
saquinavir hard gel caps 1600/100 mg once-daily together with sta-
vudine and didanosine. Before enrolment in STACCATO, patients
had participated in the HIV-NAT 001 trial series, which started in
1997, with 1 year of dual nucleoside reverse transcriptase inhibitors
(NRTI) followed by protease inhibitor-based highly active antiretro-
viral therapy (HAART).6– 8
Patients were considered eligible if they were taking saquinavir/
ritonavir for at least 4 weeks and had stable virological and
immunological profiles. Patients were excluded if they were taking
any agents that interfered with the pharmacokinetics of saquinavir
and ritonavir. Selection of patients was done randomly, based on
selecting the first 20 patients that were eligible. Following the first
pharmacokinetic assessment, patients were randomized to receive
either 2000/100 mg once-daily (arm 1) or 1000/100 mg twice-daily
(arm 2) saquinavir hard gel caps/ritonavir for 1 week. After 1 week,
all patients reverted to their original dose of saquinavir hard gel
caps/ritonavir 1600/100 mg. The NRTI backbone, stavudine and
didanosine, remained unchanged. Before the study, each patient
signed informed consent and approval was obtained from the Insti-
tutional Review Board of King Chulalongkorn University.
Safety assessment
Safety and tolerability were assessed at screening and on both phar-
macokinetic study days. During these visits, the patient history was
recorded and a physical examination carried out.
Pharmacokinetic analysis
Two pharmacokinetic curves per patient were recorded on day 0
and day 7 after randomization. On the pharmacokinetic study days,
all patients received the study treatment with a standardized break-
fast (approximately 500 calories and 12 g of fat). Other meals were
also standardized, and no other foods were allowed. Furthermore,
patients were counselled to maintain their lifestyle (smoking, con-
sumption of alcohol and exercise level) during the entire study.
Blood was sampled before (t = 0) and 2, 4, 6, 8, 10 and 12 h after
treatment intake, and, for the once-daily arm (arm 1), an additional
sample was taken at 24 h. The blood samples were centrifuged at
1500 r.p.m. and the separated plasma was stored at 20.08C until
analysis.
Plasma concentrations of saquinavir and ritonavir were analysed
at the HIV-NAT pharmacokinetic laboratory by validated high-
performance liquid chromatographic assay (HPLC).9 The HIV-NAT
pharmacokinetic laboratory participates in an international quality
control and quality assessment (QA/QC) pharmacokinetic pro-
gramme, and therefore has cross-validation with other international
pharmacokinetic laboratories.10 The lower limit of quantification
(LLOQ) was 0.04 mg/L for both protease inhibitors.
Determination of pharmacokinetic parameters was based on indi-
vidual plasma concentration data versus time by non-compartmental
analysis. The area under the curve, AUC0 – 12 or AUC0 – 24, was
defined as the area under the plasma concentration–time curve until
the last measurable plasma concentration calculated with the linear
trapezoidal method. Depending on the dosing regimen—twice-daily
or once-daily—AUC0 – 12 or AUC0 – 24 was calculated. In order to
compare AUC0 – 12 with AUC0 – 24, AUC0 – 12 was multiplied by two
where needed. This method, however, is limited because multipli-
cation by two implies that the drug levels do not show diurnal
variation. Diurnal variation has been shown for ritonavir.11 The
maximum observed plasma concentration during the dosing interval
was defined as Cmax (mg/L). The observed time to reach Cmax was
defined as Tmax (h). The minimum observed concentration just
before the next dosing interval was defined as Cmin (mg/L). Finally,
t1/2 (h) was calculated using ln(2/l). The definition of t1/2 was the
apparent elimination half-life associated with the terminal slope of
a semi-logarithmic concentration–time curve in which l is the
elimination rate constant.
Statistical analysis
Statistical analysis was carried out using SPSS software version 9.0
(SPSS, Chicago, USA, Inc., 1989–1999) and Excel 1997 (Microsoft
Corporation, 1985–1997). Pharmacokinetic parameters were log-
transformed before statistical analysis. The geometric mean ratio
(GMR) and associated 90% confidence interval (CI) were calculated
for each pharmacokinetic parameter. Patient characteristics such as
age, sex, height and weight are tabulated.
Results
Sixteen females and four males participated in the study, with a
median age of 33 years (interquartile range 29–35 years), and
all 20 patients completed it. Baseline characteristics of study
participants are illustrated in Table 1.
One patient, randomized to 1000/100 mg twice-daily, had
diarrhoea on day 0 and day 7; the investigator did not feel that
this was related to study medication. The patient had comparable
pharmacokinetic results to other patients in the study and was
included in the pharmacokinetic analysis. No other side effects
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were reported. Five patients had used other co-medication during
the study period, but this was categorized as unlikely to interfere
with the pharmacokinetics of saquinavir or ritonavir.
The median plasma concentrations of saquinavir are plotted
(Figure 1). In the first arm, patients were randomized to receive
2000/100 mg saquinavir/ritonavir once-daily. By means of visual
inspection, the rates of the absorption phase of 1600/100 mg
once-daily and 2000/100 mg once-daily appear quite similar.
The mean AUC of saquinavir in the 2000/100 mg once-daily
regimen was 71% higher than the mean AUC of saquinavir
when dosed at 1600/100 mg once-daily. Furthermore, a parallel
increase in mean saquinavir Cmin and Cmax of 65% and 52%,
respectively, was seen in the 2000/100 mg once-daily group
compared with the 1600/100 mg once-daily group. The interpati-
ent variability in the 2000/100 mg once-daily arm (arm 1), at
day 7, was less than the interpatient variability at the first phar-
macokinetic assessment (1600/100 mg once-daily).
Looking at the pharmacokinetic parameters for ritonavir,
the mean Cmax and Cmin were, as expected, similar in the
1600/100 mg once-daily group and the 2000/100 mg once-daily
group. However, there was a modest increase of 23% in mean
ritonavir AUC (90% CI 4–46%) (Tables 2 and 3). Median
plasma concentrations of ritonavir are plotted in Figure 2.
In the second arm, patients were randomized to 1000/100 mg
twice-daily saquinavir/ritonavir. The absorption of 1000/100 mg
twice-daily appeared to be slower than the absorption of
1600/100 mg once-daily or 2000/100 mg once-daily (Figure 1).
Comparing the saquinavir pharmacokinetic parameters of
1000/100 mg twice-daily with those of 1600/100 mg once-daily,
there was a large increase in Cmin when dosed as 1000/100 mg
twice-daily. Additionally, the mean saquinavir AUC increased
by 53% when dosed as 1000/100 mg twice-daily. The values for
mean saquinavir Cmax of both regimens were similar.
The interpatient variability for saquinavir Cmin was in a simi-
lar range (68% versus 73%), expressed as coefficient of vari-
ation. The saquinavir Cmax and AUC of 1000/100 mg twice-daily
dose were associated with an increase in interpatient variability.
The total daily dose of ritonavir in the 1000/100 twice-daily arm
(arm 2) was double the dose of the once-daily regimen. As
expected, mean Cmax, Cmin and AUC for ritonavir showed
increases when dosed at 1000/100 mg twice-daily (Tables 2
and 3). Three patients on 1600/100 mg once-daily had a saquina-
vir trough level lower than the recommended trough level of
0.1 mg/L of saquinavir.12 All three levels increased above the
recommended trough level on day 7.
Discussion
The pharmacokinetics of both saquinavir/ritonavir 1000/100 mg
twice-daily and saquinavir/ritonavir 1600/100 mg once-daily in
HIV-1-infected patients have been described before.3,13,14 In this
study, the pharmacokinetics of two doses, saquinavir/ritonavir
2000/100 mg once-daily and 1000/100 mg twice-daily, were
compared with the pharmacokinetics of 1600/100 mg once-daily.
Saquinavir/ritonavir when dosed as 2000/100 mg once-daily
or 1000/100 mg twice-daily showed increased AUC and Cmin
compared with when dosed as 1600/100 mg once-daily. Only the
saquinavir Cmax increased in the 2000/100 mg once-daily arm
(arm 1), whereas there was no change in saquinavir Cmax in the
1000/100 mg twice-daily arm (arm 2). Overall, pharmacokinetic
parameters improved with the 2000/100 mg once-daily dose,
whereas the Cmin improved markedly with the 1000/100 mg
twice-daily dose.
Increasing the dose of saquinavir from 1600/100 mg once-
daily to 2000/100 mg twice-daily gave a higher saquinavir
exposure. Two observations can be made from these findings.
First, the increase in saquinavir exposure is more than dose
proportional, thereby suggesting non-linear kinetics of saquinavir
when combined with low doses of ritonavir. The increase can be
explained as the result of ongoing processes: the continuation of
saquinavir absorption; the inhibition of P450 enzymes in the gut
and liver leading to decreased first-pass metabolism and, per-
haps, inhibition of P-glycoprotein.15,16
Second, the absorption of saquinavir is not maximal when
dosed as 1600 mg once-daily. This observation is in contrast
to healthy volunteer data for saquinavir/ritonavir. Dosing of
saquinavir/ritonavir as 1800/100 mg once-daily led to lower
saquinavir plasma exposure.15 However, there were limitations
in the healthy volunteer study: a relatively small number of
patients; a lack of intrapatient comparison; and a different diet-
ary composition from that of this study.
In the 1000/100 mg twice-daily arm, both the saquinavir and
ritonavir daily dosages were higher than with the 1600/100 mg
Figure 1. Median concentrations of saquinavir (SQV) (1600/100 mg) on day
0 of arm 1, saquinavir (2000/100 mg) on day 7 of arm 1, saquinavir
(1600/100 mg) on day 0 of arm 2 and saquinavir (1000/100 mg) on day 7 of
arm 2. Diamonds, arm 1, SQV 1600 mg once-daily on day 0; triangles, arm
1, SQV 2000 mg once-daily on day 7; squares, arm 2, SQV 1600 mg once-
daily on day 0; crosses, arm 2, SQV 1000 mg twice-daily on day 7.
Table 1. Patient characteristics
Characteristic OD arm (1) BD arm (2)
Age (years)
Mean 31.0 34.4
S.D. 4.6 6.2
Median 31.0 34
Weight (kg)
Mean 44.3 54.5
S.D. 5.1 9.5
Median 44.0 54.3
Height (cm)
Mean 154.5 159.5
S.D. 5.0 7.4
Median 154.5 157.0
Gender, M/F 1/9 3/7
OD, once-daily; BD, twice-daily; M, male; F, female.
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once-daily dosing. As might be expected, the exposure of saqui-
navir was higher. The marked increase in Cmin is striking, most
likely because of increased ritonavir exposure, which enhances
the inhibiting effect of P450 in the gut and the liver. Again, the
role of P-glycoprotein cannot be excluded. The lack of differ-
ence between the Cmax values of the 1600/100 mg once-daily
and the 1000/100 mg twice-daily dosing suggests that the absorp-
tion of saquinavir is lower for 1000/100 mg twice-daily dosing.
Drug levels in this study were higher than reported levels for
Caucasian patients.17 This can be partly explained by the high
number of females in this study (4:1).18 A recent study showed
that female HIV-infected patients had a higher saquinavir level
compared with male HIV-infected patients.15 Other potential fac-
tors that might be of influence are the characteristics of the
patients such as body composition, life-style, genetic background
and environmental factors. More studies are needed to examine
the effect of these differences on the clinical pharmacokinetics
of diverse patient populations.
Limitations in this study were no intrapatient comparison
between 2000/100 mg once-daily and 1000/100 mg twice-daily
Table 3. Change in pharmacokinetic parameters (GMR with 90% CI)
SQV/RTV 1600/100 mg OD ! 2000/100 mg OD
GMR 90% CI GMR 90% CI
SQV Cmax 1.52 1.23–1.88 RTV Cmax 1.16 1.00–1.34
SQV Cmin 1.65 1.09–2.49 RTV Cmin 1.01 0.65–1.57
SQV AUC0 – 24 1.71 1.27–2.29 RTV AUC0 – 24 1.23 1.04–1.46
SQV/RTV 1600/100 mg OD ! 1000/100 mg BD
GMR 90% CI GMR 90% CI
SQV Cmax 0.97 0.70–1.33 RTV Cmax 1.57 1.17–2.11
SQV Cmin 3.99 2.47–6.43 RTV Cmin 7.11 4.22–11.98
SQV AUC0 – 24 1.53 1.08–2.16 RTV AUC0 – 24 2.27 1.75–2.93
GMR, geometric mean ratio; CI, confidence interval; Cmax, maximum observed concentration; Cmin, minimum observed concentration; AUC, area under the
curve; Tmax, time to reach Cmax; SQV, saquinavir; RTV, ritonavir; OD, once-daily; BD, twice-daily.
Table 2. Pharmacokinetic parameters (means ± S.D.)
Arm 1
(n = 10)
Day 0
SQV/RTV 1600/100 mg OD
Day 7
SQV/RTV 2000/100 mg OD
SQV RTV SQV RTV
Cmax (mg/L) 6.5 ± 3.59 1.49 ± 0.64 8.85 ± 3.40 1.66 ± 0.57
Cmin (mg/L) 0.32 ± 0.28 0.06 ± 0.07 0.46 ± 0.23 0.06 ± 0.04
AUC0 – 24 (mg·h/L) 53.95 ± 29.92 12.87 ± 5.51 82.00 ± 30.01 15.65 ± 6.47
Tmax (h) 4.80 ± 1.03 4.40 ± 2.07 5.40 ± 0.97 4.00 ± 1.89
t1/2 (h) 4.68 ± 0.76 3.95 ± 1.41 4.35 ± 0.55 3.47 ± 0.79
V/kg 7.13 ± 6.33 1.18 ± 0.67 4.04 ± 1.78 0.79 ± 0.21
CL/kg 1.03 ± 0.82 0.22 ± 0.13 0.64 ± 0.27 0.17 ± 0.09
Arm 2
(n = 10)
Day 0
SQV/RTV 1600/100 mg OD
Day 7
SQV/RTV 1000/100 mg BD
SQV RTV SQV RTV
Cmax (mg/L) 4.09 ± 1.84 1.39 ± 0.75 3.89 ± 2.30 2.17 ± 1.22
Cmin (mg/L) 0.28 ± 0.19 0.07 ± 0.09 1.02 ± 0.74 0.40 ± 0.28
AUC0 – 24 (mg·h/L) 36.62 ± 18.74 12.33 ± 5.09 55.33 ± 35.08
a 28.87 ± 16.67a
Tmax (h) 5.80 ± 1.48 5.60 ± 2.95 5.20 ± 1.40 3.00 ± 1.41
t1/2 (h) 4.80 ± 0.68 4.59 ± 3.35 3.58 ± 1.50 3.50 ± 0.83
V/kg 7.04 ± 3.63 1.19 ± 1.14 3.84 ± 1.47 1.41 ± 0.51
CL/kg 0.99 ± 0.39 0.17 ± 0.06 0.80 ± 0.30 0.29 ± 0.12
Cmax, maximum observed concentration; Cmin, minimum observed concentration; AUC, area under the curve; Tmax, time to reach Cmax; t1/2, terminal half-life;
V, volume of distribution; CL, clearance; SQV, saquinavir; RTV, ritonavir; OD, once-daily; BD, twice-daily.
aAUC0 – 122.
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dosing. Conclusions regarding comparison of these two regimens
should be drawn with caution. Despite randomization, different
baseline values for weight were seen between the first and the
second arm. However, we can assume that the contribution to
the differences between the pharmacokinetics on day 0 and day
7 is low, because of intrapatient comparison.
High saquinavir levels were seen in both arms on day 7. Low
body weights at baseline in arm 1 might contribute to this effect.
The relationship between body weight and saquinavir is not
clear yet. However, an inverse correlation between body weight
and saquinavir AUC was observed in a previous study in Thai
HIV patients.13
The recommended 1000/100 mg twice-daily dose can be used
in place of the 400/400 mg twice-daily dosing regimen so as to
minimize side effects caused by higher doses of ritonavir.11,19 In
our study, no side effects were seen in the once-daily arm (arm
1). One patient had diarrhoea on both pharmacokinetic days, but
this did not seem to be related to the study agents. No other side
effects were reported. However, patients were tolerating saquina-
vir/ritonavir for a minimum of 4 weeks and a mean of 48 weeks
before this pharmacokinetic study. Nevertheless, as a result of
higher doses of saquinavir or ritonavir, additional side effects
might have appeared with intake for longer than 1 week.
A high pill burden is a potential disadvantage of protease
inhibitors in general. Changing the saquinavir dose from a
twice-daily to once-daily regimen increases the number of saqui-
navir capsules to be taken at the same time (from five in the
twice-daily regimen to between eight and 10 in the once-daily
regimen).
A new 500 mg formulation of saquinavir is currently being
developed.20 With the new formulation, a reduction in daily pill
count can be achieved. The results from our study have shown
that 2000/100 mg once-daily or 1000/100 mg twice-daily would
result in more favourable pharmacokinetic parameters than the
1600/100 mg once-daily dosage and presumably the new formu-
lation alternative dosage of 1500/100 mg once-daily as well.
The critical pharmacokinetic parameter that best predicts
in vivo antiviral efficacy of boosted saquinavir has not been
determined. The clinical efficacy of the saquinavir/ritonavir
1000/100 mg twice-daily regimen has been demonstrated in the
MaxCmin trials.21,22 There is a concern that the 1600/100 mg
once-daily dose is too low compared with the recommended
1000/100 mg twice-daily regimen, resulting in a lower trough
level and, consequently, an increased likelihood of selecting
drug-resistant HIV strains.
In our study, three patients on 1600/100 mg once-daily had
trough levels lower than the recommended target trough level for
treatment-naive patients with wild-type virus.12 Despite these low
levels, the patients had virological suppression up to 48 weeks.
In a previous study within the HIV-NAT 001 trial series, low
trough levels were also seen with saquinavir 1600/100 mg. How-
ever, patients safely switched from 1600/100 mg once-daily
saquinavir soft gel caps to 1600/100 mg once-daily saquinavir
hard gel caps and maintained their immunological and virologi-
cal response without additional side effects.3 Whether this means
that a lower trough level is acceptable, that the concomitant
NRTIs are of more importance or perhaps that intracellular
saquinavir concentration is the key parameter for predicting anti-
viral efficacy is difficult to say.23 Moreover, in both the pre-
viously mentioned switch study and our present study, the effects
of selection bias cannot be ruled out because patients were using
saquinavir hard gel caps 1600/100 mg once-daily long term.
In conclusion, dosing of saquinavir/ritonavir as 2000/100 mg
once-daily or 1000/100 mg twice-daily resulted in increased
saquinavir AUC and Cmin, whereas the saquinavir Cmax only
increased when dosed as 2000 mg.
Both dose-regimens can be used in clinical practice. Dosing
as 2000/100 mg is an attractive option because of the conven-
ience of once-daily dosing. However, it can be hypothesized that
in patients with viral resistance, the twice-daily regimen would
result in better outcomes, because of high saquinavir levels
during the entire dosing interval.
Whether one of these regimens has better clinical efficacy
needs to be investigated in a larger clinical trial. Furthermore,
studies are required to establish whether AUC, Cmin or perhaps
another pharmacokinetic parameter should be the primary con-
sideration when evaluating pharmacokinetic values associated
with different saquinavir/ritonavir dosing regimens.
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